Anticholinergic drugs are first-line pharmacotherapy for overactive bladder syndrome. They block muscarinic receptors at the detrusor muscle, thus reducing bladder contractility. As no anticholinergic drugs are totally selective for the detrusor, adverse effects from muscarinic receptor blockade at other sites are common. New drugs with greater bladder selectivity and extended-release preparations are being developed to try to reduce these adverse effects. Most of the newer drugs have similar efficacy in reducing the symptoms of overactive bladder (when compared to placebo). Optimum benefit is obtained when the drugs are prescribed in conjunction with bladder retraining.
Introduction
Overactive bladder (previously called 'unstable bladder') is a clinical symptom complex characterised by urgency (sudden and compelling desire to pass urine, which is difficult to defer), usually with frequency (more than eight voids per day) and nocturia (waking to void more than once at night). It occurs with or without urge incontinence (involuntary leakage of urine with the feeling of urgency) in the absence of infection or other irritative lesions. 1 The urodynamic diagnosis is now termed detrusor overactivity (previously called detrusor instability) because detrusor contractions are seen during filling cystometry and these are associated with the feeling of urgency. 1 There are three categories of detrusor overactivity: neuropathic (previously detrusor hyperreflexia), obstructive (commonly associated with prostatic obstruction) and idiopathic. The term overactive bladder usually refers to the idiopathic type of detrusor overactivity.
The prevalence of overactive bladder increases with advancing age and affects about 16% of adults over 40. 2 Of these, about 30% suffer from urge incontinence, now called 'overactive bladder wet', with profound reduction in quality of life. 
Rationale for anticholinergic use

Which is the most effective anticholinergic?
Uncertainty still remains about which of the anticholinergic drugs is superior in efficacy, in different patient groups (male, female, elderly) and for particular symptoms. There are also few data on the socioeconomic impact of overactive bladder symptoms or therapy. 4 
Oxybutynin
Oxybutynin is the most widely used anticholinergic for overactive bladder. Early studies showed a major clinical benefit in 60% of patients (versus 3% of those on placebo) in both objective and urodynamic assessments. Dry mouth is the most bothersome and frequent adverse effect (greater than 50%) and is associated with high discontinuation rates. 5 The drug is comparatively inexpensive.
Propantheline
Propantheline is an old drug that is still widely used in Australia. It is a synthetic analogue of atropine that blocks muscarinic receptors at all sites, thus adverse effects can be severe at low serum concentrations. However, propantheline is 60% of the cost of oxybutynin.
Imipramine
Imipramine is a tricyclic antidepressant with beta 3 mimetic properties that relax the dome of the detrusor, but it also has significant anticholinergic effects. Drowsiness is common, especially in the first three weeks of therapy while a steady state concentration is achieved. Imipramine may therefore be useful for treating nocturia or nocturnal enuresis.
Tolterodine
Tolterodine is an anticholinergic specifically developed to treat overactive bladder. In vitro, tolterodine has greater specificity for bladder tissue than for salivary glands. A meta-analysis found only four appropriate randomised controlled trials comparing tolterodine with oxybutynin. 6 Both drugs are of similar efficacy, with oxybutynin being slightly superior on some outcomes such as incontinence episodes per 24 hours. 6 The exact mechanism is not understood, but tolterodine halves the incidence of dry mouth compared to oxybutynin. 6 
Trospium
Trospium is a non-selective antimuscarinic drug which is frequently used in the UK as second-line therapy. It is as effective as oxybutynin, but has a lower incidence of adverse effects (similar to tolterodine). 7 Trospium's structure limits its penetration of the blood-brain barrier and this is thought to reduce central nervous system adverse effects. This feature may be important for elderly patients.
Darifenacin
The efficacy of darifenacin, including quality of life, has been convincingly shown over placebo, but whether there is clear superiority over drugs such as tolterodine remains to be seen.
Darifenacin has high M 3 receptor specificity, resulting in less impairment of cognitive or cardiac function. Some patients still develop dry mouth and constipation as M 3 receptor activity is present in the gut.
Solifenacin
Solifenacin was approved in the USA in 2004. In vitro, it is more selective for bladder tissue than for salivary glands.
Studies suggest improvements over placebo with low rates of dry mouth (10%) and greater quality of life. 8 A well-powered comparative randomised controlled trial 8 found that tolterodine had a lower incidence of unwanted effects and lower discontinuation rates.
Extended-release products
Extended-release formulations of oxybutynin 9 
What to prescribe
Oxybutynin should be regarded as first-line drug therapy. It fulfils criteria for cost-effectiveness, safety, efficacy, and for a significant proportion of patients, tolerability. Consideration should always be given to behavioural therapies as an adjunct, to achieve and maintain good therapeutic outcomes at the lowest drug doses. 10 Patients experiencing unmanageable adverse effects from oxybutynin may benefit from changing to second-line treatments such as tolterodine. Subsequent treatment failure may warrant specialist referral.
Only two small longitudinal studies on the duration of treatment have been carried out. Those patients who require anticholinergic therapy may typically need it for at least 3-6 months.
Minimising adverse effects
In the elderly or patients with a low bodyweight, the initial oxybutynin dose should be 2.5 mg twice daily. One can increase a morning dose or add a lunchtime dose according to the severity and timing of the urge symptoms. On the other hand, if the patient has a very dry mouth in the morning, then a lower morning dose with a larger evening dose can be used. The maximum dose is 5 mg three times daily. Tolterodine is expensive and not subsidised by the Pharmaceutical Benefits Scheme so some patients may prefer to take it in the morning and use a cheaper drug at times when dry mouth may be less bothersome.
Conclusion
Anticholinergics are clinically and statistically better than placebo for overactive bladder. Most are equally effective and all have some adverse effects. This has driven the development of drugs with greater selectivity or tolerability. Until these new alternatives undergo rigorous comparative trials, oxybutynin will remain first-line in pharmacotherapy in Australia. Outcomes are improved when anticholinergics are prescribed in conjunction with bladder training.
